|
71 |
Improvement of functional outcome for patients with newly diagnosed grade 2 or 3 gliomas with co-deletion of 1p/19q – IMPROVE CODEL: the NOA-18 trial
Enthalten in BMC cancer Bd. 22, 13.6.2022, Nr. 1, date:12.2022: 1-12
|
|
|
|
72 |
Integrated genetic analyses of immunodeficiency-associated Epstein-Barr virus- (EBV) positive primary CNS lymphomas
Enthalten in Acta neuropathologica Bd. 146, 26.7.2023, Nr. 3, date:9.2023: 499-514
|
|
|
|
73 |
INTERCEPT H3: a multicenter phase I peptide vaccine trial for the treatment of H3-mutated diffuse midline gliomas
Enthalten in Neurological research and practice Bd. 5, 19.10.2023, Nr. 1, date:12.2023: 1-6
|
|
|
|
74 |
Long-term CSF responses in adult patients with spinal muscular atrophy type 2 or 3 on treatment with nusinersen
Enthalten in Journal of neurology Bd. 272, 14.3.2025, Nr. 4, date:4.2025: 1-17
|
|
|
|
75 |
Longitudinal analysis of quality of life following treatment with Asunercept plus reirradiation versus reirradiation in progressive glioblastoma patients
Enthalten in Journal of neuro-oncology Bd. 145, 2.11.2019, Nr. 3, date:12.2019: 531-540
|
|
|
|
76 |
Loss over 5% of chromosome 1p is a clinically relevant and applicable cut-off for increased risk of recurrence in meningioma
Enthalten in Acta neuropathologica Bd. 148, 8.8.2024, Nr. 1, date:12.2024: 1-4
|
|
|
|
77 |
Neurocognitive functioning and health-related quality of life in adult medulloblastoma patients: long-term outcomes of the NOA-07 study
Enthalten in Journal of neuro-oncology Bd. 148, 4.5.2020, Nr. 1, date:5.2020: 117-130
|
|
|
|
78 |
Neurocognitive impairment and patient–proxy agreement on health-related quality of life evaluations in recurrent high-grade glioma patients
Enthalten in Quality of life research Bd. 31, 18.8.2022, Nr. 11, date:11.2022: 3253-3266
|
|
|
|
79 |
Oligosarcomas, IDH-mutant are distinct and aggressive
Enthalten in Acta neuropathologica Bd. 143, 30.12.2021, Nr. 2, date:2.2022: 263-281
|
|
|
|
80 |
Outcome analysis for patients with subarachnoid hemorrhage and vasospasm including endovascular treatment
Enthalten in Neurological research and practice Bd. 5, 2.11.2023, Nr. 1, date:12.2023: 1-10
|
|
Administration
